food%20allergy%20(pediatric)
FOOD ALLERGY (PEDIATRIC)
Food allergy is an adverse reaction due to a specific immune response occurring reproducibly upon exposure to certain foods. It occurs minutes to hours after food consumption.
Immunological mechanisms can be IgE mediated, non-IgE mediated or mixed IgE and non-IgE mediated.
It may be life-threatening and is the most common cause of anaphylaxis in children.
It should be differentiated from food intolerance in which adverse reactions from exposure to food arise from non-immunological mechanisms.
Drug Information

Indication: Relief of symptoms associated w/ allergic rhinitis & common cold including nasal congestion, sneezing, rhi...

Indication: Relief of symptoms associated w/ allergic rhinitis & common cold including nasal congestion, sneezing, rhi...

Indication: Symptomatic relief of allergic rhinitis eg, sneezing, nasal discharge & itching, as well as ocular itching...

Indication: Management of reversible bronchospasm associated w/ obstructive airway disease in patients who require more th...

Indication: Tab/Syr Relief of all bronchial asthma, chronic bronchitis & emphysema. Evohaler Relief & prevention o...

Indication: Symptomatic treatment of seasonal & perennial allergic rhinitis & urticaria of allergic origin.

Indication: Rapid relief of symptoms associated w/ allergic rhinitis eg, sneezing, nasal discharge & itching, congesti...

Aerius D-12
desloratadine + pseudoephedrine sulphate

Indication: Symptomatic relief of nasal & non-nasal allergic rhinitis including nasal congestion in adults & child...

Indication: Relief of symptoms associated w/ allergic rhinitis & common cold eg, nasal congestion, sneezing, rhinorrhe...

Indication: Symptomatic treatment of perennial & seasonal allergic rhinitis, vasomator rhinitis, allergic conjunctivit...

1  /  12
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 27 Jun 2019

A 2-week course of the immunotherapy drug teplizumab delayed the onset of type 1 diabetes (T1D) in individuals at high risk for the condition, according to a phase II trial conducted by the TrialNet Study Group and presented at ADA 2019.